The Non-Hodgkin Lymphoma Partnering 2010-2015 report provides understanding and access to the non-hodgkin lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies.

The Non-Hodgkin Lymphoma Partnering 2010-2015 provides understanding and access to the non-hodgkin lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of non-hodgkin lymphoma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors non-hodgkin lymphoma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 35 links to online copies of actual non-hodgkin lymphoma deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of non-hodgkin lymphoma partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of non-hodgkin lymphoma technologies and products.

Report scope

Non-Hodgkin Lymphoma Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to non-hodgkin lymphoma trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in non-hodgkin lymphoma dealmaking in the biopharma industry since 2010Access to summary headline, upfront, milestone and royalty dataAccess to over 35 non-hodgkin lymphoma dealsThe leading non-hodgkin lymphoma deals by value since 2010

In Non-Hodgkin Lymphoma Partnering 2010-2015, the available deals are listed by:

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...